Загальні відомості про зниження еритропоезу

ЗаGloria F. Gerber, MD, Johns Hopkins School of Medicine, Division of Hematology
ПереглянутоJerry L. Spivak, MD; MACP, , Johns Hopkins University School of Medicine
Переглянуто/перевірено Змінено бер. 2025
v968961_uk

Anemia, a decrease in the number of red blood cells (RBCs), hemoglobin (Hb) content, or hematocrit (Hct), can result from decreased RBC production (erythropoiesis), increased RBC destruction, blood loss, or a combination of these factors. (See also Approach to the Patient with Anemia.)

Anemias due to decreased erythropoiesis (termed hypoproliferative anemias) are recognized by a reticulocyte count that is inappropriately low for the degree of the anemia.

The RBC indices, mainly the mean corpuscular volume (MCV), can narrow the differential diagnosis of deficient erythropoiesis and help determine what further testing is necessary.

Microcytic anemias result from deficient or defective heme or globin synthesis. Microcytic, hypoproliferative anemias include

Patients with a microcytic anemia typically require evaluation of iron stores.

Normocytic anemias are characterized by a normal MCV (80 to 100 fL) and normochromic indices. The two most common causes are

Acquired primary bone marrow disorders such as aplastic anemia, pure red cell aplasia, and myelodysplastic syndrome (MDS) can also manifest with a normocytic anemia.

Macrocytic anemias can be caused by impaired DNA synthesis leading to megaloblastosis, as occurs with

Other causes of macrocytic anemia include

Some patients with hypothyroidism have macrocytic RBC indices, including some without anemia.

Anemias can have variable findings on the peripheral smear. The anemia of chronic disease may be microcytic or normocytic. Anemias due to myelodysplastic syndromes may be normocytic, macrocytic, or even microcytic. Anemias due to endocrine disorders (such as hypothyroidism) or elemental deficiencies (eg, copper deficiency) can have variable manifestations, including a microcytic, normocytic, or macrocytic anemia.

Treatment of deficient RBC production depends on the cause.

Еритропоетин та Дарбепоетин в якості речовин, якими зловживають

Erythropoietin and darbepoetin may be used to increase production of red blood cells in patients with certain types of anemia. These agents are sometimes taken by athletes to increase red cell production in order to increase the cells' oxygen-carrying capacity, which can enhance performance especially in endurance events.

Using erythropoietin or darbepoetin without medical need may alter normal regulation of red blood cell production, so that red blood cell production suddenly decreases when these agents are stopped.